ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,114.63
      -0.01%
      US Tech 100
      21,524.40
      0.41%
      Dow Jones
      44,546.08
      -0.37%
      Brent Oil
      74.39
      0.00%
      Bitcoin
      97,009.61
      -0.60%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Oruka Therapeutics Inc (ORKA) Quote

      Oruka Therapeutics Inc

      Oruka Therapeutics Inc (ORKA)

      NASDAQ
      11.18
      -0.25
      (-2.19%)
      Closed February 16 4:00PM
      Delayed by 15 minutes
      11.05
      -0.13
      (-1.16%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      11.18
      Bid
      10.75
      Ask
      19.09
      Volume
      248,876
      10.83 Day's Range 11.905
      10.61 52 Week Range 31.13
      Market Cap
      391.284M
      Previous Close
      11.43
      Open
      11.17
      Last Trade
      5
      @
      11.27
      Last Trade Time
      Financial Volume
      $ 2,821,293
      VWAP
      11.3361
      Average Volume (3m)
      322,927
      Shares Outstanding
      34,998,550
      Dividend Yield
      -
      PE Ratio
      -72.46
      Earnings Per Share (EPS)
      -0.15
      Revenue
      -
      Net Profit
      -5.34M

      About Oruka Therapeutics Inc

      ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome ... ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Show more

      Sector
      In Vitro,in Vivo Diagnostics
      Industry
      In Vitro,in Vivo Diagnostics
      Website
      www.orukatx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Oruka Therapeutics Inc is listed in the In Vitro,in Vivo Diagnostics sector of the NASDAQ with ticker ORKA. The last closing price for Oruka Therapeutics was $11.43. Over the last year, Oruka Therapeutics shares have traded in a share price range of $ 10.61 to $ 31.13.

      Oruka Therapeutics currently has 34,998,550 shares outstanding. The market capitalization of Oruka Therapeutics is $400.03 million. Oruka Therapeutics has a price to earnings ratio (PE ratio) of -72.46.

      Ask ADVFN Intelligence (AI)

      ORKA Latest News

      More News

      Form 8-K - Current report
      Edgar (US Regulatory)
      February 05 2025
      ORKA (-2.19%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 24 2025
      ORKA (-2.19%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 24 2025
      ORKA (-2.19%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 24 2025
      ORKA (-2.19%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 24 2025
      ORKA (-2.19%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      December 19 2024
      ORKA (-2.19%)

      Form EFFECT - Notice of Effectiveness
      Edgar (US Regulatory)
      November 27 2024
      ORKA (-2.19%)

      Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
      Edgar (US Regulatory)
      November 21 2024
      ORKA (-2.19%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-1.83-14.066102997713.0113.4710.6138735711.20492142CS
      4-1.52-11.96850393712.715.110.6129344512.21955727CS
      12-9.23-45.222929936320.4125.6510.6132292717.49784582CS
      26-17.82-61.44827586212931.1310.6121366119.6841539CS
      52-17.82-61.44827586212931.1310.6121366119.6841539CS
      156-17.82-61.44827586212931.1310.6121366119.6841539CS
      260-17.82-61.44827586212931.1310.6121366119.6841539CS

      ORKA - Frequently Asked Questions (FAQ)

      What is the current Oruka Therapeutics share price?
      The current share price of Oruka Therapeutics is $ 11.18
      How many Oruka Therapeutics shares are in issue?
      Oruka Therapeutics has 34,998,550 shares in issue
      What is the market cap of Oruka Therapeutics?
      The market capitalisation of Oruka Therapeutics is USD 400.03M
      What is the 1 year trading range for Oruka Therapeutics share price?
      Oruka Therapeutics has traded in the range of $ 10.61 to $ 31.13 during the past year
      What is the PE ratio of Oruka Therapeutics?
      The price to earnings ratio of Oruka Therapeutics is -72.46
      What is the reporting currency for Oruka Therapeutics?
      Oruka Therapeutics reports financial results in USD
      What is the latest annual profit for Oruka Therapeutics?
      The latest annual profit of Oruka Therapeutics is USD -5.34M
      What is the registered address of Oruka Therapeutics?
      The registered address for Oruka Therapeutics is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
      What is the Oruka Therapeutics website address?
      The website address for Oruka Therapeutics is www.orukatx.com
      Which industry sector does Oruka Therapeutics operate in?
      Oruka Therapeutics operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      JTAIJet AI Inc
      $ 6.02
      (133.33%)
      		104.48M
      SRMSRM Entertainment Inc
      $ 0.6999
      (95.50%)
      		254.39M
      WRDWeRide Inc
      $ 31.4877
      (83.39%)
      		21.07M
      INLFINLIF Limited
      $ 16.27
      (80.58%)
      		7.68M
      MBRXMoleculin Biotech Inc
      $ 2.1201
      (66.94%)
      		136.66M
      BLACBellevue Life Sciences Acquisition Corporation
      $ 3.08
      (-56.31%)
      		430.77k
      BLACUBellevue Life Sciences Acquisition Corporation
      $ 3.36
      (-52.68%)
      		5.21k
      CSAICloudastructure Inc
      $ 19.0001
      (-49.58%)
      		1.03M
      NEXNNexxen International Ltd
      $ 10.30
      (-49.16%)
      		164.82k
      BSLKBolt Projects Holdings Inc
      $ 0.6626
      (-46.13%)
      		13.4M
      CNSPCNS Pharmaceuticals Inc
      $ 0.1415
      (31.26%)
      		489.28M
      MGOLMGO Global Inc
      $ 0.7176
      (-15.08%)
      		417.31M
      SRMSRM Entertainment Inc
      $ 0.6999
      (95.50%)
      		254.39M
      INTCIntel Corporation
      $ 23.60
      (-2.20%)
      		230.26M
      NVDANVIDIA Corporation
      $ 138.85
      (2.63%)
      		194.99M

      Discussion

      View Full Feed
      JSmith5 JSmith5 4 minutes ago
      hhmm - not sure the event or policy that causes this

      I don't see the commons dropping below the current level - almost regardless of what happens. However, that being said - do the the letters SPS and SWF mean anything to you? Its not beyond the realm of possibility - a full, or eve
      FNMA
      Zardiw Zardiw 4 minutes ago
      Nice to listen to on a Sunday Morning:

      https://youtu.be/3iucUsL08KM

      Z
      Zardiw Zardiw 5 minutes ago
      Nice to listen to on a Sunday Morning:

      https://youtu.be/3iucUsL08KM

      Z
      TAZMANS TAZMANS 5 minutes ago
      $NBRI $$ Adding more next week, chart and news! GOLD, Mill and Mines(s)

      Business Plan Developed at $2000/2200 per oz GOLD last year IMO; today, going into our launch and ramp-up of our mill, mine(s) $2800/3000!

      CHART:
      Accumulation is at a record high today, our p
      CMC NBRI
      ITYS ITYS 6 minutes ago
      Maybe take 20 mins and have someone educated read it to you :-)
      Company loses millions each Quarter...not sure where this potential comes from?
      GEVI
      Zardiw Zardiw 6 minutes ago
      Nice to listen to on a Sunday Morning:

      https://youtu.be/3iucUsL08KM

      Z
      rickstereo3333 rickstereo3333 6 minutes ago
      Do you read before posting or is it an issue with actual reading and comprehending what you read!?!?


      Per my patently clear post.......
      How do sprint meetings work?
      - The company and the FDA agree on a single topic and a set time period for discussion
      RDGL
      Sodapop42 Sodapop42 6 minutes ago
      LMAO, no Satoshi, if you click on your name, it has how many posts you have, nah, a good laugh yes!!
      PHIL
      TAZMANS TAZMANS 7 minutes ago
      $NBRI $$ Adding more next week, chart and news! GOLD, Mill and Mines(s)

      Business Plan Developed at $2000/2200 per oz GOLD last year IMO; today, going into our launch and ramp-up of our mill, mine(s) $2800/3000!

      CHART:
      Accumulation is at a record high today, our p
      CMC NBRI
      nowwhat2 nowwhat2 7 minutes ago
      Oh well okay there mr great silkworm genius......Why don' you try then enlightening us all ?
      The only thing you do is draw lines on obvious historical actions LOL

      https://investorshub.advfn.com/uimage/uploads/2025/2/16/fzypibtc_o_17_HYPER_NON_ETCH_60000_magnet.jpg
      XRPUSD
      ddls ddls 8 minutes ago
      Why don't you tell us exactly what is going to save BIEL.

      Point by point, line item by line item.

      If you can instead of "boy are you in for a big surprise"
      BIEL
      TAZMANS TAZMANS 8 minutes ago
      $NBRI $$ Adding more next week, chart and news!

      Business Plan Developed at $2000/2200 per oz GOLD last year IMO; today, going into our launch and ramp-up of our mill, mine(s) $2800/3000!

      CHART:
      Accumulation is at a record high today, our price WAS .0016 the last
      CMC NBRI
      learningcurve2020 learningcurve2020 9 minutes ago
      Actually his post is nothing like that report. One deals with future predictions and the other with past events.
      NWBO
      sortagreen sortagreen 9 minutes ago
      Canada has laws. Apparently they can impound funds being used to facilitate a criminal enterprise.
      cojoboy cojoboy 10 minutes ago
      Wow..you count them..???..in you little head 24/7..???😂😂😂
      PHIL
      oldstocks oldstocks 11 minutes ago
      Binding Letter of Intent whereby MTI shareholders will exchange their ownership interest for equity of Affluence Corporation. The companies are working diligently towards closing, anticipated in the first quarter of 2025.

      The first quarter is half way over.

      Closing coul
      AFFU
      tombe tombe 12 minutes ago
      Sorry Ib_. Actually it won’t let me reply through a private message. I tried. I will answer your question publicly though. Yes, I do trust Nasrat to do what is best for shareholders. I have always trusted him and understand that none of us have the information or knowledge to second guess w
      ELTP
      Semper Fi 88 Semper Fi 88 12 minutes ago
      Everybody should listen to this especially newbies.
      FNMA
      weedtrader420 weedtrader420 13 minutes ago
      XRP GOING TO $5.75 Will become #2 🪙🖕35🤡
      XRPUSD
      ignatiusrielly35 ignatiusrielly35 13 minutes ago
      Le Charlatan is a clown, posting basic charts with a vague meme-like comment that makes no actual prediction. Then, no matter what happens, he tries to take credit for it. Classic delusions of grandeur filled with bragging of his non-existent expertise. Its best to just hit the ignore button as I di
      XRPUSD
      ilovetech ilovetech 13 minutes ago
      Yep, it certainly looks to be playing out that way.

      Here's how sales of Provenge have fared since it gained approval:
      Annual revenue for Provenge has varied over the years, including $228 million in 2011, $303 million in 2016, and less than $500 million in 2021. Explanation
      NWBO
      Donotunderstand Donotunderstand 14 minutes ago
      If true (Mnuchin disregarded DJT and listened to GS)

      Then shame on DJT
      DJT
      jour_trader jour_trader 15 minutes ago
      He really emphasized the word "yet". 
      ELTP

      Your Recent History

      NASDAQ
      ORKA
      Oruka Therapeutics
      BIT
      UC2XXJ
      Unicredit Bank
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads